Valuation: TG Therapeutics, Inc.

Market Cap 6.91B 6B 5.59B 5.14B 9.71B 657B 9.82B 65.92B 25.77B 328B 25.94B 25.37B 1,088B P/E 2026 *
52.9x
P/E 2027 * 16.2x
Enterprise Value 6.9B 5.99B 5.59B 5.13B 9.71B 657B 9.81B 65.88B 25.75B 328B 25.92B 25.35B 1,087B EV / Sales 2026 *
7.23x
EV / Sales 2027 * 4.8x
Free-Float
88.55%
Yield 2026 *
-
Yield 2027 * -
1 day+5.56%
1 week-11.18%
Current month-6.33%
1 month-8.58%
3 months+36.49%
6 months+67.36%
Current year+63.49%
1 week 45.36
Extreme 45.365
54.34
1 month 45.36
Extreme 45.365
59.3
Current year 26.76
Extreme 26.76
59.3
1 year 25.28
Extreme 25.28
59.3
3 years 6.46
Extreme 6.46
59.3
5 years 3.48
Extreme 3.48
59.3
10 years 3.32
Extreme 3.32
59.3
Manager TitleAgeSince
Chief Executive Officer 60 28/12/2011
Director of Finance/CFO 44 28/12/2011
Investor Relations Contact - 30/11/2011
Director TitleAgeSince
Chairman 60 28/12/2011
Director/Board Member 79 29/02/2012
Director/Board Member 62 08/11/2012
Date Insider Type Main position Quantity % Market Cap.
28/01/26 Don

Director

43,197 0.0272%
08/01/26 Free

Chief Executive Officer

622,000 0.3918%
08/01/26 Free

Chief Financial Officer

90,000 0.0567%
Change 5-day change 1-year change 3-year change Capi.($)
+5.56%-11.18%+69.69%+355.04% 6.91B
-0.51%-8.60%+45.08%+148.21% 995B
+0.20%-4.42%+49.05%+50.81% 614B
-0.53%-7.37%+23.64%+65.03% 431B
+1.26%-0.44%+40.99%+35.96% 353B
+0.42%-3.88%+30.62%+38.79% 293B
-0.42%-11.54%+3.55%+6.72% 245B
-6.51%-13.27%-4.15%-46.27% 210B
+2.94%-0.78%+29.17%+60.32% 210B
+3.13%+0.69%+18.11%+71.90% 168B
Average +0.68%-5.64%+30.57%+78.65% 352.52B
Weighted average by Cap. +1.43%-5.90%+33.54%+70.89%

Financials

2026 *2027 *
Net sales 955M 829M 773M 710M 1.34B 90.81B 1.36B 9.11B 3.56B 45.39B 3.58B 3.51B 150B 1.31B 1.14B 1.06B 976M 1.85B 125B 1.87B 12.53B 4.9B 62.41B 4.93B 4.82B 207B
Net income 151M 131M 122M 112M 212M 14.37B 215M 1.44B 564M 7.18B 567M 555M 23.8B 490M 426M 397M 365M 690M 46.65B 697M 4.68B 1.83B 23.32B 1.84B 1.8B 77.27B
Net Debt -4.69M -4.07M -3.8M -3.49M -6.6M -446M -6.67M -44.77M -17.5M -223M -17.62M -17.23M -739M -601M -522M -487M -447M -846M -57.19B -855M -5.74B -2.24B -28.59B -2.26B -2.21B -94.73B
Logo TG Therapeutics, Inc.
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Employees
399
Date Price Change Volume
04/08/26 US$48.74 +5.56% 2,865,716
03/08/26 US$46.17 -11.26% 6,421,976
31/07/26 US$52.03 -2.80% 2,489,895
30/07/26 US$53.53 +0.09% 2,851,516
29/07/26 US$53.48 -2.53% 2,916,396
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
48.74USD
Average target price
68.57USD
Spread / Average Target
+40.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TGTX Stock